Post-SELEX Optimization and Characterization of a Prostate Cancer Cell-Specific Aptamer for Diagnosis

Esther Campos-Fernández, Leticia S. Barcelos, Aline G. Souza, Luiz R. Goulart, and Vivian Alonso-Goulart*

ABSTRACT: The RNA aptamer A4 binds specifically to tumor prostate cells. A4 was modified (mA4) by adding deoxyribonucleotides to its ends to remove the reactive 2′ hydroxyl groups of RNA’s sugar at the ends of the aptamer and to make it more stable to widespread RNase contamination in laboratories. Thus, mA4 would be more suitable to use in the clinical settings of prostate cancer (PCa). We aimed to characterize this optimized oligonucleotide to verify its potential as a diagnostic tool. The sequences and structures of A4 and mA4 were compared through in silico approaches to corroborate their similarity. Then, the degradation of mA4 was measured in appropriate media and human plasma for in vitro tests. In addition, the binding abilities of A4 to prostate cells were contrasted with those of mA4. The effects of mA4 were assessed on the viability, proliferation, and migration of human prostate cell lines RWPE-1 and PC-3 in three-dimensional (3D) cell cultures. mA4 showed configurational motifs similar to those of A4, displayed a half-life in plasma substantially higher than A4, and exhibited a comparable binding capacity to that of A4 and unaltered viability, proliferation, and migration of prostatic cells. Therefore, mA4 maintains the crucial 3D structures of A4 that would allow binding to its target, as suggested by in silico and binding analyses. mA4 may be a good PCa reporter as it does not change cellular parameters of prostate cells when incubated with it. Its additional deoxyribonucleotides make mA4 inherently more chemically stable than A4, avoiding its degradation and favoring its storage and handling for clinical applications. These characteristics support the potential of mA4 to be used in diagnostic systems for PCa.

1. INTRODUCTION

According to the Surveillance, Epidemiology, and End Results (SEER) Program from the National Cancer Institute in the United States, patients with metastatic stage of prostate cancer (PCa) diagnosis showed a five-year relative survival of only 30.5%, while patients with localized or regional lymph node stage at diagnosis had a five-year relative survival of 100% between 2009 and 2015. Consequently, the substantial gap between these two populations of patients suggests that the stage of PCa at diagnosis is crucial for patient survival rates and earlier diagnoses and treatments could improve them.2

PCa is screened by prostate-specific antigen (PSA) blood test, sometimes complemented by digital rectal examination. After a positive result, PCa is confirmed by histopathological examination of a biopsy.3 In the cases of negative ultrasound-guided biopsy in men with a high probability of sampling error, most urologists use prostate multiparametric magnetic resonance imaging (MRI) for PCa diagnosis.4 However, conflicting recommendations for the use of PSA in the clinical management of PCa5,6 evidenced that PSA is an unspecific biomarker with questionable utility in some cases.

On the one hand, high levels of PSA may not indicate PCa. In fact, PSA is produced by other glands, under other conditions and found even in females.7 Thus, there is a high chance of false-positive results with up to 67% of over-diagnosed and overtreated patients.8 On the other hand, about a quarter of men with low PSA levels have PCa and are underdiagnosed.9 In addition, PSA testing does not avoid the biopsy procedure for diagnosis, which is also susceptible of false-negatives because of sampling errors.10 These facts support the re-assessment of PSA and the search for more accurate and definitive biomarkers for the diagnosis and monitoring of PCa.

The approaches that analyze tumor components released in body fluids are called liquid biopsies.11 These liquid biopsies represent the current state of a cancer in an individual and their sampling is less invasive than surgical biopsies.12 Among other constituents, tumors release cells that may be detected in blood. These cells are known as circulating tumor cells (CTCs). The expression of surface markers on CTCs and their
quantification have already been studied as factors for the clinical management of several cancers.\(^{13}\) For PCa, CTCs in blood samples are the most researched target in liquid biopsies.\(^{14}\)

In this view, our research group used the prostate cell lines PC-3 and RWPE-1 as positive and negative targets, respectively, to select ligands of PCa CTCs by the systematic evolution of ligands by exponential enrichment in three-dimensional cell cultures (3D Cell-SELEX).\(^{15}\) This technology yielded several RNA aptamers that bind specifically to PC-3 cells. The A4 aptamer was one of the selected aptamers which showed a small size and a low free energy according to the minimum free energy (MFE) structure by the Sfold web server.\(^{16}\) Owing to these desirable characteristics in aptamers, A4 was further characterized, showing a high affinity for PC-3 cells.\(^{15}\) Therefore, we theorized that A4 may be used as a diagnostic tool which detects PCa CTCs in blood samples from patients.

However, factors and enzymes that degrade RNAs are highly efficient, as they show complementary and frequently reiterative mechanisms. In fact, RNAs may pose a great threat to the humans. For example, noncoding RNAs may interfere in the regulation of gene expression and viral RNAs may replicate to infect host cells.\(^{17}\) RNA aptamers are chemically more unstable than DNA aptamers because of their 2′ hydroxyl group that makes them more susceptible to hydrolysis and ribonuclease action.\(^{18,19}\)

However, wobble base pairs in RNA aptamers, such as guanosine–uridine bonds, allow for more complex 3D structures, when compared to DNA structures.\(^{20}\) For these reasons, we maintained the unique sequence of the original RNA aptamer with its more intricate design and we added DNA ends with their higher chemical stability to a new version of A4 called mA4. The rest of the original RNA aptamer corresponds to sequences complementary to the primers used in the selection process that are identical in the other aptamers.

At the 5′ end, we changed the sugar of nucleotides 1 to 14 to deoxyribose to improve RNase resistance and added a thymine spacer of 13 nucleotides. This spacer is important to avoid potential steric hindrance because of the interaction of the coupled biotin with labeled avidin molecules and allow target recognition.\(^{21}\) At the 3′ end, we changed the sugar of nucleotides 44 to 46 to deoxyribose and replaced the uracil base 46 with thymine, a canonical base in DNA, again to improve RNase resistance.

Thus, we combined the advantages of the two types of nucleotides in mA4, with the intention of reducing its susceptibility to degradation without perturbing its putative binding motifs. In the present work, we use in silico approaches to verify the similar composition and structure of A4 and mA4 and in vitro approaches to compare their resistance to nuclease in plasma and cell culture media. Enzyme-linked apta-sorbent assay (ELASA) is also used to prove whether mA4 maintains the binding profile of A4.

In addition to being specific and resistant to nuclease, nucleotide-based probes should not be prone to induce undesirable biological changes in order to be implemented in theranostic applications. Accordingly, we also characterize the biological effects of mA4 on the viability, proliferation, and migration of human prostate cell lines used to select it. The
PC-3 cell line was isolated from bone marrow and it displays an androgen-independent growth, being considered a good model of advanced prostate adenocarcinoma22 and later of prostatic small cell carcinoma.23 Differently, RWPE-1 cell line was developed from the immortalization of nontumorigenic prostatic epithelial cells with human papilloma virus 18 representing a benign prostatic epithelium, which is androgen-sensitive.24

With these human cell lines, we can delimit the potential clinical uses of mA4 in the management of PCa patients. Thus, we hypothesize that mA4, the optimized version of A4, can also be used as a diagnostic tool for PCa.

2. RESULTS AND DISCUSSION

2.1. Sequence of mA4 is Similar to That of A4. mA4 maintained the specific RNA sequence of A4 without the common flanking sequences for amplification and with additional random deoxyribonucleotides at both ends and a poly-T linker at the 5′ end for biotin coupling. The BLAST25 algorithm showed a good alignment between the all-DNA versions of the mA4 and A4 aptamers (Figure 1A). This alignment displayed an expect value of 3 × 10−23 and a score match of 86.1, with an 83% of cover and 100% of identity between the 46 common nucleotides. Consequently, mA4 has a similar sequence to that of A4, with a high-scoring segment. Most of the nucleotides of the two sequences were identical or homolog. As homolog nucleotides are able to maintain the function in aptamers with the same sequence, but different types of sugar in their nucleotides,26 mA4 may retain the binding abilities and affinities of A4.

2.2. In Silico Prediction of mA4 Folding Displays Potential Binding Structures. The most probable secondary structure of mA4 showed two single strands at the termini, three helical stems with two asymmetrical internal loops, and a hairpin tetraloop closed by a guanosine–uridine wobble base pair (Figure 1B). This structure displayed the lowest free energy (ΔG = −16.784 kcal/mol) with a GC content of 49.15%, which increased to 62.07% in the RNA region, and a melting temperature of 73.6 °C. Compared to A4,15 mA4 showed a free energy only 0.8 kcal/mol higher, one less weak guanosine–uridine bond, a high percentage of guanosine and cytosine bases, and a melting temperature 3.1 °C lower than that of A4. Therefore, mA4 is slightly more unstable than A4, but considering that its thymine spacer is the main difference between them and that it makes the mA4 sequence less stable, we ponder that mA4 still is a stable single-stranded oligonucleotide.

The longest strings of the two asymmetrical internal loops and the hairpin loop of mA4 share their RNA sequences and consensus motifs with conformations found in the secondary structure of A4.15 Because secondary structures of aptamers, such as hairpins, bulges, pseudoknots, G-quadruplexes, and so forth, provide information about relevant regions of binding because they establish noncovalent interactions with the target molecule,27,28 we defined three potential binding domains from the in silico prediction of mA4 folding. Potential binding domain I (PBD I) consists of nucleotides 25–29, PBD II consists of nucleotides 33–36, and PBD III consists of nucleotides 44–50 (Figure 1B). The mA4 tertiary structure also shows these three putative binding sites among the three helical stems (Figure 1C). These common architectural motifs are crucial, as 3D shapes are responsible for high-affinity noncovalent bindings between aptamers and their target molecules.29 Consequently, the 59-mer aptamer (mA4) would be able to bind to PC-3 cells in a similar way to that of the original 55-mer aptamer (A4).

2.3. mA4 Shows Resistance to Nucleases under the Tested Conditions. Prior to the biological assays, the in vitro stability of mA4 to nucleases was evaluated for 72 h in the RPMI-1640 medium and Keratinocyte serum-free medium (SFM) used to culture human tumor prostate PC-3 cells and human nontumor prostate RWPE-1 cells, respectively. Over this period, its half-life was 4.1 h in RPMI-1640 medium and 1.5 h in Keratinocyte-SFM, showing time-dependent degradation profiles (Figure 2A). Moreover, the fluorescence of ethidium bromide intercalated into the nucleotides of mA4 was conserved under the two conditions analyzed in the agarose gel (Figure 2C). This fact shows that a portion of mA4 remained...
aptamers need di...

... the selection process of aptamers, comparable to the traditional tubes for blood collection inhibits the action of endogenous resistance of DNA to blood plasma nucleases, the anticoagu-

... target are organized in structural motifs shared with the sca... silico studies and the ELASA suggest that mA4 may produce a...

... as both bind to PC-3 cells and do not bind to RWPE-1 cells, in comparison with the controls (Figure 3). In addition, the absence of the statistical difference between the binding of A4 and mA4 with PC-3 cells may indicate that they attach to these cells with comparable forces, in a similar way. Therefore, mA4 maintains the binding specificity of A4 to prostate cells.

... Although other studies, such as nuclear magnetic resonance spectroscopy, are needed to verify that a modified aptamer has mimetic structures of the native one,35 our results from the in silico studies and the ELASA suggest that mA4 may produce a scaffold on which nucleotides that interact with its molecular target are organized in structural motifs shared with the original sequence of A4.

... viability in Keratinocyte-SFM was faster than that in RPMI-1640. However, this apparent higher resistance to nuclease in RPMI-1640 may be put down to the differences in the nuclease profiles of the media36 rather than to conformation changes in the aptamer. In addition, mA4 was coupled with biotin, which would further protect it from nucleases.31

mA4 and A4 were also incubated in human blood plasma to test and compare their resistance to nucleases present in this biological fluid. mA4 demonstrated to be almost 25-fold more resistant to nuclease action than A4 (Figure 2B), with a half-life of 7.1 h, compared to the half-life of A4 which was only 0.3 h (18 min) in human plasma. It is remarkable that the staining profile of A4 fades after 0.5 h (Figure 2D).

Our results are similar to others comparing RNA and DNA aptamers, as they are in the same order of magnitude. For example, comparing anti-thrombin aptamers in human plasma, DNA aptamers were degraded after 7 h, while RNA aptamers remained only 10 min.32 Apart from the intrinsic higher resistance of DNA to blood plasma nucleases, the anticoagulant ethylenediamine tetraacetic acid (EDTA) used in the tubes for blood collection inhibits the action of endogenous DNases,33 favoring longer half-lives of present DNAs, including DNA aptamers incubated in blood plasma. The higher resistance to nuclease of mA4 makes it a better candidate for a future clinical diagnosis system with blood plasma as a sample used to detect PCa by liquid biopsy.

2.4. mA4 Binds Specifically to PC-3 Cells. Because the ELASA is an easy, fast, and cost-effective technique to monitor the selection process of aptamers, comparable to the traditional flow cytometry approach,34 we used ELASA to compare the binding of mA4 and A4 to prostate cell lines used for A4 selection.

mA4 and A4 showed specificity in their binding, as both bind to PC-3 cells and do not bind to RWPE-1 cells, in comparison with the controls (Figure 3). In addition, the absence of the statistical difference between the binding of A4 and mA4 with PC-3 cells may indicate that they attach to these cells with comparable forces, in a similar way. Therefore, mA4 maintains the binding specificity of A4 to prostate cells.

Although other studies, such as nuclear magnetic resonance spectroscopy, are needed to verify that a modified aptamer has mimetic structures of the native one,35 our results from the in silico studies and the ELASA suggest that mA4 may produce a scaffold on which nucleotides that interact with its molecular target are organized in structural motifs shared with the original sequence of A4.

2.5. Viability of Prostate Cells Grown under In Vivo-Like Conditions is Unaffected by mA4. Because different aptamers need different times to interact with their targets36 and produce a cellular response, we considered an interval of 48 h which is long enough to assess the potential effects of mA4 on cell lines. Consequently, these potential effects could be extrapolated to those of mA4 in a clinical sample tested for diagnosis, considering the necessary laboratory procedures and handling. In vitro assays were performed on the epithelial cell lines RWPE-1 and PC-3, as they were used in the negative and positive selections of the A4 aptamer, respectively. Although RWPE-1 cells are nonneoplastic human prostate cells and they represented the nontarget cells, PC-3 cells are neoplastic human prostate cells and they represented the target cells, which the aptamer should bind to in a potential diagnostic or treatment system.

Viability of prostate cells cultured in magnetic 3D bioprinting was unaffected by the presence of mA4 at concentrations of 2.5 and 5 μM, after 24 and 48 h of incubation (Figure 4). A4 did not affect the viability of prostate cells under the tested conditions either (Figure S1).

Despite cell viability remaining an issue for CTC isolation methods that use aptamers for diagnosis from human fluids, it is hard to find in the literature, cell viability tests with aptamers for diagnostic use. Contrary to our findings, most aptamers trigger cell death responses when they bind to their target cells, being used as therapeutic tools rather than diagnostic ones. For example, anti-EpCAM, anti-CD44, and bispecific anti-EpCAM-CD44 aptamers, at concentrations up to 4 μM, reduced the viability of ovarian tumor cell lines, which was correlated to the expression of these targets in the cells, after 72 h of incubation.37

The fact that mA4 did not kill its target cells PC-3 means that it could be used as a diagnostic tool reporting the presence of a molecular biomarker. If needed and tested, mA4 could report such a biomarker for a long period after its binding, as it does not kill the bearing cell. Besides being used as a diagnostic tool, this result does not exclude its use as a therapeutic tool. However, mA4 would need to be coupled with a drug to act as a targeted drug delivery system.

2.6. Prostatic Cells Proliferate at Their Normal Rate in the Presence of mA4 in an In Vivo-Like System. As cell viability is intimately related to cell proliferation, but not all viable cells are dividing, we tested cell proliferation of our prostate cell lines. PC-3 and RWPE-1 cells also maintained...

https://dx.doi.org/10.1021/acsomega.9b03855
ACS Omega 2020, 5, 3533−3541
their proliferation ability (Figure 5), after incubation with mA4 for 48 h. Similar to our results, the incubation of the aptamer AS1411 with its target hepatocarcinoma cells failed to show significant differences in their proliferation profile at a concentration twice as high as the maximum concentration used by us, whereas when this aptamer was modified with the replacement of two internal thymines by two 5-(N-naphthylcarboxamidine)-2′-deoxyuridines to increase its affinity to its target nucleolin, it decreased the proliferation of these cells under the same conditions. Therefore, modifications that improve the interaction between aptamers and their targets could induce biological changes in target cells.

In contrast to our results of PC-3 cells, most aptamers decrease cell proliferation when they bind to their target cells whose target molecules are involved in the signaling of growth factors. Thus, our results suggest that if the target molecule is involved in cell proliferation pathways, either the concentration of mA4 used in the proliferation assay, the expression of its molecular target in PC-3 cells, or the interactions between them are not enough to induce changes in the cell proliferation of PC-3 cells.

However, the concentrations used were higher to those previously reported by other researchers. For example, the RA16 aptamer, with its molecular target unknown, reduced the proliferation of its target cells NCI-H460 at a concentration of 300 nM, six times lower than the highest concentration used in our study. The U2 aptamer also decreased proliferation of glioblastoma cells at even lower concentrations, 25 and 50 nM, and after incubation for 24 and 48 h. Accordingly, the expression of the molecular target of mA4 may be low to induce observable changes in the proliferation of PC-3 cells. Another possibility is that the interaction between them is too weak and it needs to be enhanced.

2.7. mA4 Does Not Influence Migration of Prostatic Cell Lines. When these prostate cells were cultured in a monolayer, under the same conditions, the wound healing assay did not show significant differences in their migration profile, compared to the controls, after incubation with mA4 (Figure 6) or A4 (Figure S2) for 24 and 48 h. Although 3D cultures better mimic in vivo conditions and should be considered the first choice for in vitro tests, we did not find an alternative to replace the wound healing assay which is performed in two-dimensional (2D) cultures. However, the results of this assay were consistent with those of cell viability and proliferation that we performed in 3D cultures.

Differently, the aptamer AXL reduced the migration of the ovary cancer cells SKOV3-IP1 after 24 and 48 h of incubation at a concentration of 100 nM. The aptamer U2 also decrease the migration of target glioblastoma multiforme cells, after 8 and 24 h of incubation at 50 nM, a concentration a hundredfold lower than our maximum concentration. Interestingly, the aptamer CL4, which shares the receptor EGFRvIII as its target with the aptamer U2, showed that the decrease in the migration of the target cells depends not only on the presence of the target but also on the expression of downstream proteins in the signaling pathways of its target. Therefore, we cannot rule out the chance that the target molecule of mA4 is involved
which allowed us to increase our knowledge about mA4 and its interaction with prostatic cells. Because mA4 bound specifically to tumor prostate cells, is more resistant than A4 to nuclease present in plasma, and did not affect the behavior of prostate cells, we determine that mA4 can be directly used in in vitro diagnostic systems for PCA.

The potential use of mA4 in other theranostic applications, such as diagnostic imaging and treatment systems, still requires further investigation. mA4 did not showed therapeutic action itself against PCA cells. However, mA4 could be used as a targeted drug carrier, coupled with a drug, to avoid toxic effects in nontarget cells, which often limits the effect of treatments.\textsuperscript{47} As A4 and mA4 bind to PCA cells through molecular targets unknown to date,\textsuperscript{15} it would be interesting to identify the target molecule and its binding region to predict other potential biological actions of the aptamer in its target cells and to improve their interaction.\textsuperscript{36,49} Future findings will hopefully broaden the clinical applications of mA4.

### 4. MATERIALS AND METHODS

#### 4.1. Aptamers.

Integrated DNA Technology (IDT, Coralville, IA, USA) synthesized mA4 and A4 and biotinylated them at their 5’ ends. The sequence of the RNA aptamer A4 was synthesized with its unique nucleotides without the sequences complementary to the primers used during its selection process (5’GGGCCGACGCAGCACGGCCAGGUAAGCACAACCGCGCAT3’).\textsuperscript{15} This sequence was truncated and deoxyribonucleotides were added at its ends to design the aptamer mA4 yielding the following sequence, with the deoxyribonucleotides underlined: 5’TCCCCCCGAGGUAAGCAAAACCACGCCCGCAUCGUCC3’. The sequences of both aptamers were aligned using BLAST\textsuperscript{25} to identify common nucleotides.

#### 4.2. In Silico Elucidation of Secondary and Tertiary Structures.

The secondary structure of mA4 was predicted using the Mfold web server (https://www.idtdna.com/Unafold/Home/Index).\textsuperscript{50} This secondary structure was translated into the dot-bracket notation (Vienna format) to be imported to the RNA Composer web server (http://rnacomposer.ibch.poznan.pl/Home),\textsuperscript{51} which predicted the tertiary structure of the RNA form of the aptamer.

The Discovery Studio Visualizer software (Dassault Systèmes BIOVIA, v19.1.0.18287, San Diego, CA, USA) was used to adapt the 3D RNA form of the aptamer to its 3D chimeric form, with its additional deoxyribonucleotides.

#### 4.3. Aptamer Degradation Assay.

Both RPMI-1640 (Cultilab, Campinas, SP, Brazil) and Keratinocyte-SFM (Thermo Fisher Scientific, Waltham, MA, USA) were supplemented with 100 µg/mL gentamicin (Thermo Fisher Scientific, Waltham, MA, USA), incubated with mA4 at a concentration of 33.34 µM at 37 °C for 0, 0.5, 1, 2, 4, 8, 24, 48, and 72 h, and then frozen at −80 °C.

Three blood samples were collected in tubes with EDTA (Vacuette K3EDTA, Greiner Bio-one, Kremsmünster, Austria) from PCA patients, together with the corresponding informed consent. This experiment was approved by the Research Ethics Committee of the Federal University of Uberlândia (CAAE 71108817.2.0000.5152) in accordance with all national and local guidelines and regulations.

After venipuncture, the tubes were centrifuged at 2000g for 15 min at 4 °C and the supernatants were mixed and used to incubate the aptamers A4 and mA4 separately, at a

---

**Figure 6. Effects on prostatic cell migration induced by mA4.** (A) Wound closure percentage of PC-3 cells. (B) Wound closure percentage of RWPE-1 cells. The data represent the means ± standard errors of the means of two independent experiments, run in triplicate, resulting from a wound healing assay of the prostatic cell lines incubated with no aptamer (control) and with mA4 at 2.5 and 5 µM for 24 and 48 h. One-way analysis of variance with Tukey post-test was used to analyze the different conditions, *p < 0.05. C. Representative images of the wound healing assays of the cell lines treated with 5 µM of mA4 after 0, 24, and 48 h. Magnification × 10. Scale bar 400 µm.
concentration of 33.34 μM at 37 °C for 0, 0.5, 1, 2, 4, 6, 8, 10, and 24 h. Then, the solutions were frozen at −80 °C.

The degradation of the aptamers at each time and in each diluent was analyzed after electrophoresis on a 2% agarose gel stained with ethidium bromide (Sigma-Aldrich, Saint Louis, MO, USA). The bands were imaged and their intensity were quantified using ImageJ program (v1.52o, NIH, Bethesda, MD, USA). A molecular-weight size marker (MM) of 100 pair bases (DNA Ladder 100 pb, Ludwig Biotecnologia, Alvorada, RS, Brazil) was used to assist in identifying the aptamers on the gel. Supplemented media or human blood plasma without aptamers were used as controls. Data were normalized considering fluorescence intensity at time 0 h as 100%. Exponential one-phase decay equation was used to get the half-life of mA4 and A4 under the tested in vitro conditions by PrismGraph program (GraphPad Software, v.7, La Jolla, CA, USA).

4.4. Cell Cultures. PC-3 (ATCC CRL-1435) and RWPE-1 (ATCC CRL-11609) human prostate cell lines (ATCC, Manassas, VA, USA) were cultured in a monolayer and 3D bioprinting was used for the in vitro assays. Both cell lines were successfully authenticated in 2018 by short tandem repeat analysis and monthly tested for mycoplasma contamination with negative results.

The PC-3 cell line was cultured in RPMI-1640 medium (Cultilab, Campinas, SP, Brazil), and the RWPE-1 cell line was cultured in Keratinocyte-SFM (Thermo Fisher Scientific, Waltham, MA, USA). Both cell lines were supplemented with 100 μg/mL gentamicin (Thermo Fisher Scientific, Waltham, MA, USA) and 10% fetal bovine serum (Gibco/Thermo Fisher Scientific, Waltham, MA, USA) and incubated at 37 °C in a 5% CO2 atmosphere. After trypsinization with 0.25% trypsin–EDTA solution (Corning, New York, NY, USA), cells were seeded on either plates for adherent monolayer cell culture or ultralow adhesion plates (Corning, New York, NY, USA) for 3D cell culture, according to each assay. Bio Assembler kits (Nano3D Biosciences, Houston, TX, USA) were used for 3D bioprinting, according to the manufacturer’s instructions.

4.5. Enzyme-Linked Apta-sorbent Assay. A day before the experiment, cells were plated in monolayers, in 96-well plates at a density of 5 × 104. Cells were blocked with phosphate buffer saline (PBS) containing 5% bovine serum albumin for 1 h at 37 °C followed by washing with PBS and incubation with 2 μM biotinylated aptamers A4 and mA4 for 1 h at 37 °C. After washing with PBS, cells were incubated with streptavidin-conjugated horseradish peroxidase (SAv-HRP) (BD Biosciences Pharmingen, San Diego, CA, USA) diluted (1:250) in PBS for 1 h at 37 °C. The wells were washed again with PBS, and the peroxidase reaction was initiated by orthophenylene diamine dihydrochloride (OPD) (Sigma-Aldrich, Saint Louis, MO, USA) in citrate-phosphate buffer with 3% H2O2 and terminated upon addition of sulphuric acid. The absorbance of each well was measured at 492 nm in a microplate reader to estimate the binding of the aptamers. In parallel, incubation of cells with PBS was used as a negative control and incubation of cells with SAv-HRP in PBS was used for data adjustment.

4.6. Cell Viability and Proliferation Assays. Cells were seeded in 96-well plates containing 2 × 103 cells per well and grown in 3D culture. After 24 h, cells were treated with the corresponding medium with mA4 at concentrations of 2.5 and 5 μM and without mA4 (control). Cellular viability and proliferation were analyzed, after 24 and 48 h of treatment. As an assay control, cellular viability was also evaluated after incubation of A4 at a concentration of 2 μM, with an additional death control with 1% Triton 100-X (Thermo Fisher Scientific, Waltham, MA, USA). Fetal bovine serum was not used for these treatments, as it could degrade the aptamers.

Cellular viability was assessed by an absorbance-based assay, performed with the neutral red reagent (Sigma-Aldrich, Saint Louis, MO, USA), according to the manufacturer’s instructions.

Cellular proliferation was assessed by a fluorescence-based assay, performed with the CytoSelect cell proliferation assay reagent (Cell Biolabs, San Diego, CA, USA), according to the manufacturer’s recommendations.

4.7. Wound Healing Assay. In 12-well plates, 2 × 105 cells per well were grown in monolayers to full confluence. A longitudinal scratch was made with a sterile pipette tip at the bottom of each well. Wells were washed with PBS and cells were treated with the corresponding medium with mA4 at concentrations of 2.5 and 5 μM and without mA4 (control). As an assay control, cellular migration was also evaluated after incubation of A4 at a concentration of 2 μM. Fetal bovine serum was not used for the treatments, as it could degrade the aptamers.

Images were acquired using an EVOS inverted microscope (Thermo Fisher Scientific, Waltham, MA, USA) at 0, 24, and 48 h after the treatments. The open (wounded) areas of the images were calculated using the ImageJ program (v1.52o, NIH, Bethesda, MD, USA) to assess cell migration.

4.8. Statistical Analyses. Statistical analyses were performed by PrismGraph program (GraphPad Software, v.7, La Jolla, CA, USA). The Kruskal–Wallis test with Dunn post-test or the one-way analysis of variance (ANOVA) test with Tukey post-test was used for multiple comparisons according to each set of data. The value of p < 0.05 was considered statistically significant for all tests.

ASSOCIATED CONTENT

Supporting Information
The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsomega.9b03855.

Viability and migration of prostate cells incubated with A4 (PDF)

AUTHOR INFORMATION

Corresponding Author
Vivian Alonso-Goulart — Laboratory of Nanobiotechnology, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia 38408-100, Minas Gerais, Brazil; orcid.org/0000-0002-2041-0053; Phone: +55(34)3225-8440; Email: alonso.goulart@ufu.br

Authors
Esther Campos-Fernández — Laboratory of Nanobiotechnology, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia 38408-100, Minas Gerais, Brazil
Leticia S. Barcelos — Laboratory of Nanobiotechnology, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia 38408-100, Minas Gerais, Brazil
ACKNOWLEDGMENTS

This work was supported by the National Council for Scientific and Technological Development (CNPq), INCT-TeraNano grant number 465669/2014-0, and the Brazilian funding agency Coordination for the Improvement of Higher Education Personnel (CAPES).

REFERENCES

(1) Howlader, N.; Noone, A.; Krapcho, M.; Miller, D.; Brest, A.; Yu, M.; Ruhl, J.; Tatalovich, Z.; Mariotto, A.; Lewis, D.; et al. SEER Cancer Statistics Review, 1975–2016. https://seer.cancer.gov/csr/1975-2016/, (accessed Dec 22, 2019).
(2) Brawley, O. W. Trends in Prostate Cancer in the United States. J. Natl. Cancer Inst. Monogr. 2012, 2012, 152–156.
(3) Velonas, V.; Woo, H.; Remedios, C.; Assinder, S. Current Status of Biomarkers for Prostate Cancer. Int. J. Mol. Sci. 2013, 14, 11034–11060.
(4) Truong, M.; Frye, T. P. Magnetic Resonance Imaging Detection of Prostate Cancer in Men with Previous Negative Prostate Biopsy. Transl. Androl. Urol. 2017, 6, 424–431.
(5) Andriole, G. L.; Crawford, E. D.; Grubb, R. L.; Buyyus, S. S.; Chia, D.; Church, T. R.; Fouad, M. N.; Isaacs, C.; Kvale, P. A.; Reding, D. J.; et al. Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-Up. J. Natl. Cancer Inst. 2012, 104, 125–132.
(6) Schröder, F. H.; Hugosson, J.; Carlsson, S.; Tammela, T.; Määtänen, L.; Auvina, A.; Kwiatkowski, M.; Recker, F.; Roobol, M. J. Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur. Urol. 2012, 62, 745–752.
(7) Diamandis, E. P.; Yu, H. Nonprostatic Sources of Prostate-Specific Antigen. Urol. Clin. N. 1997, 24, 275–282.
(8) Loeb, S.; Bjurlin, M. A.; Nicholson, J.; Tammela, T. L.; Penson, D. F.; Carter, H. B.; Carroll, P.; Etzioni, R. Overdiagnosis and Overtreatment of Prostate Cancer. Eur. Urol. 2014, 65, 1046–1055.
(9) Tricoli, J. V.; Schoenfeldt, M.; Conley, B. a. Detection of Prostate Cancer and Predicting Progression: Current and Future Diagnostic Markers Detection of Prostate Cancer and Predicting Progression: Current and Future Diagnostic Markers. Clin. Cancer Res. 2004, 10, 3943–3953.
(10) Murphy, A. M.; McKiernan, J. M.; Olsson, C. A. Controversies in Cancer Screening. J. Urol. 2004, 172, 1822–1824.
(11) Marrugo-Ramírez, J.; Mir, M.; Samitier, J.; Marrugo-Ramírez, J.; Mir, M.; Samitier, J. Blood-Based Cancer Biomarkers in Liquid Biopsy: A Promising Non-Invasive Alternative to Tissue Biopsy. Int. J. Mol. Sci. 2018, 19, 2877.
(12) Brock, G.; Castellanos-Ritzaldos, E.; Hu, L.; Coticchia, C.; Skog, J. Liquid Biopsy for Cancer Screening, Patient Stratification and Monitoring. Transl. Cancer Res. 2015, 4, 280–290.
(13) Strotman, L. N.; Millner, L. M.; Valdes, R.; Linder, M. W. Liquid Biopsies in Oncology and the Current Regulatory Landscape. Mol. Diagn. Ther. 2016, 20, 429–436.
(14) Campos-Fernández, E.; Barcelos, L. S.; de Souza, A. G.; Goulart, L. R.; Alonso-Goulart, V. Research Landscape of Liquid Biopsies in Prostate Cancer. Am. J. Cancer Res. 2019, 9, 1309–1328.
(15) Souza, A. G.; Marangoni, K.; Fujimura, P. T.; Alves, P. T.; Silva, M. J.; Bastos, V. A. F.; Goulart, L. R.; Goulart, V. A. 3D Cell-SELEX: Development of RNA Aptamers as Molecular Probes for PC-3 Tumor Cell Line. Exp. Cell Res. 2016, 341, 147–156.
(16) Ding, Y.; Chan, C. Y.; Lawrence, C. E. S. Šold Web Server for Statistical Folding and Rational Design of Nucleic Acids. Nucleic Acids Res. 2004, 32, W135.
(17) Housey, J.; Tollervey, D. The Many Pathways of RNA Degradation. Cell 2009, 136, 763–776.
(18) Ulrich Göringer, H.; Adler, A.; Forster, N.; Homann, M. Post-SELEX Chemical Optimization of a Trypanosome-Specific RNA Aptamer. Comb. Chem. High Throughput Screening 2008, 11, 16–23.
(19) Wilson, C.; Keefe, A. Building Oligonucleotide Therapeutics Using Non-Natural Chemistries. Curr. Opin. Chem. Biol. 2006, 10, 607–614.
(20) Zhu, Q.; Liu, G.; Kai, M.; Zhu, Q.; Liu, G.; Kai; M. DNA Aptamers in the Diagnosis and Treatment of Human Diseases. Molecules 2015, 20, 20979–20997.
(21) Wu, C.; Liu, J.; Zhang, P.; Li, J.; Ji, H.; Yang, X.; Wang, K. A Recognition-before-Labeling Strategy for Sensitive Detection of Lung Cancer Cells with a Quantum Dot-Aptamer Complex. Analyst 2015, 140, 6100–6107.
(22) Kaighn, M. E.; Narayan, K. S.; Ohnuki, Y.; Lechner, J. F.; Jones, L. W. Establishment and Characterization of a Human Prostatic Carcinoma Cell Line (PC-3). Invest. Urol. 1979, 17, 16–23.
(23) Tai, S.; Sun, Y.; Squires, J. M.; Zhang, H.; Oh, W. K.; Liang, C.-Z.; Huang; J. PC3 Is a Cell Line Characteristic of Prostatic Small Cell Carcinoma. Prostate 2011, 71, 1668–1679.
(24) Bello, D.; Webber, M. M.; Kleinman, H. K.; Wartner, D. D.; Rhim, J. S. Androgen Responsive Adult Human Prostatic Epithelial Cell Lines Immortalized by Human Papillomavirus 18. Carcinogenesis 1997, 18, 1215–1223.
(25) Zhang, Z.; Schwartz, S.; Wagner, L.; Miller, W. A Greedy Algorithm for Aligning DNA Sequences. J. Comput. Biol. 2000, 7, 203–214.
(26) Walsh, R.; DeRosa, M. C. Retention of Function in the DNA Homolog of the RNA Dopamine Aptamer. Biochem. Biophys. Res. Commun. 2009, 388, 732–735.
(27) Stoltenburg, R.; Reinemann, C.; Strehlitz, B. SELEX—A (r)Evolutionary Method to Generate High-Affinity Nucleic Acid Ligands. Biomol. Eng. 2007, 24, 381–403.
(28) Cai, S.; Yan, J.; Xiong, H.; Liu, Y.; Peng, D.; Liu, Z. Investigations on the Interface of Nucleic Acid Aptamers and Binding Targets. Analyst 2018, 143, 5317.
(29) Ruscito, A.; DeRosa, M. C. Small-Molecule Binding Aptamers: Selection Strategies, Characterization, and Applications. Front. Chem. 2016, 4, 14.
(30) Ahirwar, R.; Nahar, S.; Aggarwal, S.; Ramachandran, S.; Maiti, S.; Nahar, P. Silico Selection of an Aptamer to Estrogen Receptor Alpha Using Computational Docking Employing Estrone Response Elements as Aptamer-Alike Molecules. Sci. Rep. 2016, 6, 21285.
(31) Ni, S.; Yao, H.; Wang, L.; Lu, J.; Jiang, F.; Lu, A.; Zhang, G. Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes. Int. J. Mol. Sci. 2017, 18, 1683.
(32) Krissanaprasit, A.; Key, C.; Fergione, M.; Froehlich, K.; Pontuis, S.; Hart, M.; Carriel, P.; Kjems, J.; Andersen, E. S.; LaBean, T. H. Genetically Encoded, Functional Single-Strand RNA Oligami: Anticoagulant. Adv. Mater. 2019, 31, 1808262.
(33) Barra, G. B.; Santa Rita, T. H.; Vasques, J. d. A.; Chianca, C. F.; Nery, L. F. A.; Costa, S. S. S. EDTA-Mediated Inhibition of DNAses Protects Circulating Cell-Free DNA from Ex Vivo Degradation in Blood Samples. Clin. Biochem. 2015, 48, 976–981.
Nabavinia, M. S.; Charbgoo, F.; Alibolandi, M.; Mosaffa, F.; Gholoobi, A.; Ramezani, M.; Abnous, K. Comparison of Flow Cytometry and ELASA for Screening of Proper Candidate Aptamer in Cell-SELEX Pool. Appl. Biochem. Biotechnol. 2018, 184, 444.

Gelinas, A. D.; Davies, D. R.; Janjic, N. Embracing Proteins: Structural Themes in Aptamer-Protein Complexes. Curr. Opin. Struct. Biol. 2016, 36, 122–132.

Missailidis, S.; Hardy, A. Aptamers as Inhibitors of Target Proteins. Expert Opin. Ther. Pat. 2009, 19, 1073–1082.

Zheng, J.; Zhao, S.; Yu, X.; Huang, S.; Liu, H. Y. Simultaneous Targeting of CD44 and EpCAM with a Bispecific Aptamer Effectively Inhibits Intraperitoneal Ovarian Cancer Growth. Theranostics 2017, 7, 1373–1388.

Cho, Y.; Lee, Y. B.; Lee, J. H.; Lee, D. H.; Cho, E. J.; Yu, S. J.; Kim, Y. J.; Kim, J. I.; Im, J. H.; Lee, J. H.; et al. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14. PLoS One 2016, 11, No. e0160822.

Wang, H.; Zhang, Y.; Yang, H.; Qin, M.; Ding, X.; Liu, R.; Jiang, Y. In Vivo SELEX of an Inhibitory NSCLC-Specific RNA Aptamer from PEGylated RNA Library. Mol. Ther. –Nucleic Acids 2018, 10, 187−198.

Zhang, X.; Peng, L.; Liang, Z.; Kou, Z.; Chen, Y.; Shi, G.; Li, X.; Liang, Y.; Wang, F.; Shi, Y. Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells. Mol. Ther. –Nucleic Acids 2018, 10, 438−449.

Souza, A. G.; Silva, I. B. B.; Campos-Fernández, E.; Barcelos, L. S.; Souza, J. B.; Marangoni, K.; Goulart, L. R.; Alonso-Goulart, V. Comparative Assay of 2D and 3D Cell Culture Models: Proliferation, Gene Expression and Anticancer Drug Response. Curr. Pharm. Des. 2018, 24, 1689.

Kanlikilicer, P.; Ozpolat, B.; Aslan, B.; Bayraktar, R.; Gurbuz, N.; Rodriguez-Aguayo, C.; Bayraktar, E.; Denizli, M.; Gonzalez-Villasana, V.; Ivan, C.; et al. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Mol. Ther. –Nucleic Acids 2017, 9, 251–262.

Camorani, S.; Crescenzi, E.; Colecchia, D.; Carpentieri, A.; Anversa, A.; Fedele, M.; Ciarelli, M.; Cerchia, L. Aptamer Targeting EGFRvIII Mutant Hampers Its Constitutive Autophosphorylation and Affects Migration, Invasion and Proliferation of Glioblastoma Cells. Oncotarget 2015, 6, 37570–37587.

Ogden, A.; Rida, P. C. G.; Reid, M. D.; Aneja, R. Interphase Microtubules: Chief Casualties in the War on Cancer? Drug Discovery Today 2014, 19, 824–829.

Thiel, K. W.; Giangrande, P. H. Therapeutic Applications of DNA and RNA Aptamers. Oligonucleotides 2009, 19, 209–222.

Imamura, Y.; Mukohara, T.; Shimono, Y.; Funakoshi, Y.; Chayahara, N.; Toyoda, M.; Kyota, N.; TAKAO, S.; KONO, S.; NAKATSURA, T. Comparison of 2D- and 3D-Culture Models as Drug-Testing Platforms in Breast Cancer. Oncol. Rep. 2015, 33, 1837–1843.

Leong, S.; McKay, M. J.; Christopherson, R. I.; Baxter, R. C. Biomarkers of Breast Cancer Apoptosis Induced by Chemotherapy and TRAIL. J. Proteome Res. 2012, 11, 1240–1250.

Yoon, S.; Rossi, J. J. Emerging Cancer-Specific Therapeutic Aptamers. Curr. Opin. Oncol. 2017, 29, 366–374.

Lee, K. Y.; Kang, H.; Ryu, S. H.; Lee, D. S.; Lee, J. H.; Kim, S. Bioimaging of Nucleolin Aptamer-Containing 5′-(N-Benzylcarboxamide)2-Deoxyuridine More Capable of Specific Binding to Targets in Cancer Cells. J. Biomed. Biotechnol. 2010, 2010, 168306.

Zuker, M. Mfold Web Server for Nucleic Acid Folding and Hybridization Prediction. Nucleic Acids Res. 2003, 31, 3406–3415.

Popenda, M.; Szachniuk, M.; Antczak, M.; Purzycka, K. J.; Lukasiak, P.; Bartol, N.; Blazewicz, J.; Adamiak, R. W. Automated 3D Structure Composition for Large RNAs. Nucleic Acids Res. 2012, 40, No. e112.